Atherotech Diagnostics Lab Expands Heart Disease Risk Assessment With AspirinWorks® Test
3/27/2013 10:49:13 AM
BIRMINGHAM, Ala.--(BUSINESS WIRE)--Atherotech Diagnostics Lab, a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions, recently launched the AspirinWorks® Test to complement its menu of cardiovascular disease risk assessment tests. More than 1 million Americans experience new or recurrent heart attacks each year. These at-risk individuals are candidates for aspirin therapy and should be tested for the presence or absence of the therapy’s effect. The AspirinWorks Test is used to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids a physician in the determination of aspirin effect.